Since 2014
Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?
Applied Economics and Finance
View Archive Info| Field | Value | |
| Title |
Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?
|
|
| Creator |
Morten Dalen, Dag
Locatelli, Marilena Sorisio, Enrico Strøm, Steinar |
|
| Description |
TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8 per cent of total pharmaceutical sale in Norway. Novelty of the paper is to examine, with the use of a unique natural policy experiment in Norway, to what extent the price responsiveness of prescription choices is affected when the identity of the third-party payer changes. The three dominating drugs in this market, Enbrel, Remicade, and Humira, are substitutes, but have had different and varying funding schemes - hospitals and the national insurance plan. A stochastic structural model for the three drugs, covering demand and price setting, is estimated in a joint maximum likelihood approach. We find that doctors are more responsive when the costs are covered by the hospitals compared to when costs are covered by national insurance.
|
|
| Publisher |
Redfame Publishing
|
|
| Contributor |
Norwegian Research Council
|
|
| Date |
2014-03-19
|
|
| Type |
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion Peer-reviewed Article |
|
| Format |
application/pdf
|
|
| Identifier |
http://redfame.com/journal/index.php/aef/article/view/324
10.11114/aef.v1i1.324 |
|
| Source |
Applied Economics and Finance; Vol 1, No 1 (2014); 39-54
2332-7308 2332-7294 |
|
| Language |
eng
|
|
| Relation |
http://redfame.com/journal/index.php/aef/article/view/324/480
|
|